

Plaintiffs' Attorneys in Heartburn Drugs Lawsuits Announce \$425M AstraZeneca Settlement But Say the Fight Is Not Over

The PSC in the national PPI litigation scored the settlement for thousands of victims for whom acid reflux drugs allegedly caused kidney injuries.

PENSACOLA, FL, UNITED STATES, October 5, 2023 /EINPresswire.com/ -- Levin Papantonio Rafferty (LPR) Attorneys [Troy Rafferty](#) and [Cameron Stephenson](#) announced a settlement victory involving thousands of lawsuits claiming AstraZeneca's heartburn drugs, Nexium and Prilosec, caused chronic kidney injuries. The settlement came after years of litigation contending that AstraZeneca knew of these risks, dating all the way back to the clinical trial phase, yet failed to warn patients and their healthcare providers.



Yesterday's \$425 million settlement for kidney injuries caused by AstraZeneca's Nexium and Prilosec drugs is an outcome of multidistrict litigation against several Big Pharma defendants. Plaintiffs' attorneys still must fight Takeda, maker of Prevacid and Dexilant.

Rafferty, a member of the Plaintiffs' Executive Committee (PEC) in the Proton-Pump Inhibitor (PPI) multidistrict litigation (MDL), said he and Stephenson are thrilled for their clients but noted litigation continues against another PPI manufacturer, Takeda.

The settlement represents partial closure in a continuing, larger litigation against manufacturers of PPI-class drugs in a New Jersey federal court before U.S. District Judge Claire C. Cecchi [MDL -2789 IN RE: Proton-Pump Inhibitor Products Liability Litigation (No. II)].

"Today's settlement announcement marks an unbelievable result for plaintiffs and victims," Rafferty said, "but this isn't over."

Rafferty referred to the fact that PPI claims against pharmaceutical giant Takeda, maker of the

drugs Prevacid and Dexilant, are still pending.

Stephenson applauded the efforts of all of the PEC and PSC law firms, noting that successful litigation against Big Pharma takes a team of lawyers who are willing to stand up to corporations in the name of what is right. The PPI MDL-2789 has been pending since 2017, costing the law firms millions of dollars and requiring thousands of litigation hours to bring about this outcome.

"I have been involved in this litigation for years," Stephenson added. "To see this result on behalf of our clients is why I do this. But now all eyes turn to Takeda. I can guarantee the PSC--this whole team of law firms--will fight even harder until Takeda pays for the damages they caused. We are more motivated now than ever."

“

Today's settlement announcement marks an unbelievable result for plaintiffs and victims, but this isn't over."

*TROY RAFFERTY, ATTORNEY,
LEVIN PAPANTONIO RAFFERTY*

Sara Stephens
Levin Papantonio Rafferty
+1 281-744-6560
sstephens@levinlaw.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)



LPR Attorney Troy Rafferty is a member of the Plaintiffs Executive Committee in MDL -2789 IN RE: Proton-Pump Inhibitor Products Liability Litigation (No. II).



LPR Attorney Cameron Stephenson has been immersed in the PPI litigation for years and is committed to ensuring drug makers inform patients about the risks they face when they take certain medications.

This press release can be viewed online at: <https://www.einpresswire.com/article/659857037>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.

Instagram
YouTube